BriaCell Therapeutics Announces Closing of Offering
Rhea-AI Summary
BriaCell Therapeutics (Nasdaq:BCTX) closed a best-efforts offering of 1,449,300 common shares at $3.25 per share, for approximately $4.7 million in gross proceeds.
According to BriaCell, net proceeds will support working capital, general corporate purposes, and advancement of business objectives.
Positive
- Raised approximately $4.7 million in gross proceeds
- Flexible use of funds for working capital and corporate purposes
- Supports advancement of business objectives in immuno-oncology
- Utilized an effective Form S-3 shelf registration for capital access
Negative
- Issuance of 1,449,300 new shares creates potential shareholder dilution
- Net proceeds will be lower than $4.7 million after fees and expenses
News Market Reaction – BCTX
In the Jun 3 session, BCTX gained 1.22%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 31 | Offering pricing | Negative | -9.1% | Priced 1,449,300-share best-efforts equity offering at $3.25 per share. |
| Jul 16 | Offering closing | Negative | +1.1% | Closed $15M public offering of 12M units with accompanying warrants. |
| Jul 15 | Offering pricing | Negative | -61.8% | Priced $15M public offering of 12M units at $1.25 per unit. |
| Apr 28 | Offering closing | Negative | -8.2% | Closed $13.8M offering of 3,066,666 units including underwriter option. |
| Apr 24 | Offering pricing | Negative | -13.8% | Priced $13.8M public unit offering with five-year warrants at $5.25. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-related announcements have typically coincided with negative price moves for BCTX, with most past financings followed by single-day declines.
Recent history for BriaCell around financings shows repeated capital raises. In April–July 2025, the company priced and closed offerings of $13.8M and $15M, generally followed by share price weakness. The latest prior event on May 31, 2026 priced the current 1,449,300-share deal at $3.25, also met with a negative reaction. Today’s closing announcement fits this pattern of equity raises used for working capital and business objectives aligning with share pressure.
Key Terms
best-efforts offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the closing of its best-efforts offering of 1,449,300 common shares. Each common share was sold at an offering price of
The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.
ThinkEquity acted as the sole placement agent for the offering.
The securities described above were offered and sold by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-276650), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 22, 2024 and declared effective on January 31, 2024. The offering was made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and can be accessed for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.
Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
